Proactive Investors - Run By Investors For Investors

Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors' Andrew Scott sits down with Arix Bioscience Plc's (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma.

Arix has recently upped its stake in Artios following a Series B financing round that was backed by the venture capital arms of industry giants Pfizer and Novartis.

Artios Pharma's developing DNA damage response technology to treat cancer.

 
Meet Location Sciences Group PLC, Itaconix Plc, Shield Therapeutics PLC and WideCells Group at our event, London , 21 March 2019. Register here »
View full ARTIO profile View Profile

Artios Pharma Ltd Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use